Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 18/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 16/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 15/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 10/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 6/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 4/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | CYP1A1 | P04798 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 3/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2471765 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A3SLC6A2CYP2D6KCNH2 | |
| SCHEMBL13272946 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A3SLC6A2CYP2D6KCNH2 | |
| SCHEMBL13273208 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A3SLC6A2CYP2D6KCNH2 | |
| SCHEMBL14889441 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A3SLC6A2CYP2D6KCNH2 | |
| SCHEMBL19749346 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A3SLC6A2CYP2D6KCNH2 | |
| SCHEMBL20209817 | 0.96 | SLC6A4 (1.00) | SLC6A4SLC6A3SLC6A2CYP2D6KCNH2 | |
| SCHEMBL21413970 | 0.96 | SLC6A4 (1.00) | SLC6A4SLC6A3SLC6A2CYP2D6KCNH2 | |
| SCHEMBL13273211 | 0.96 | SLC6A4 (1.00) | SLC6A4SLC6A3SLC6A2CYP2D6KCNH2 | |
| SCHEMBL2499160 | 0.96 | SLC6A4 (1.00) | SLC6A4SLC6A3SLC6A2CYP2D6KCNH2 | |
| SCHEMBL2494326 | 0.96 | SLC6A4 (1.00) | SLC6A4SLC6A3SLC6A2CYP2D6KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10428021-B2 | Triple reuptake inhibitors and methods of their use | SUNOVION PHARMACEUTICALS INC. (US) | 2019-10-01 | — | — | US | disclosed |
| US-10428021-B2 | Triple reuptake inhibitors and methods of their use | SUNOVION PHARMACEUTICALS INC. (US) | 2019-10-01 | — | — | US | disclosed |
| US-20180148407-A1 | TRIPLE REUPTAKE INHIBITORS AND METHODS OF THEIR USE | SUNOVION PHARMACEUTICALS INC. | 2018-05-31 | — | — | US | disclosed |
| US-20180148407-A1 | TRIPLE REUPTAKE INHIBITORS AND METHODS OF THEIR USE | SUNOVION PHARMACEUTICALS INC. | 2018-05-31 | — | — | US | disclosed |
| US-20180148407-A1 | TRIPLE REUPTAKE INHIBITORS AND METHODS OF THEIR USE | SUNOVION PHARMACEUTICALS INC. | 2018-05-31 | — | — | US | disclosed |
| US-9850204-B2 | Triple reuptake inhibitors and methods of their use | SUNOVION PHARMACEUTICALS INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-9850204-B2 | Triple reuptake inhibitors and methods of their use | SUNOVION PHARMACEUTICALS INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-9850204-B2 | Triple reuptake inhibitors and methods of their use | SUNOVION PHARMACEUTICALS INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-20160221947-A1 | TRIPLE REUPTAKE INHIBITORS AND METHODS OF THEIR USE | SUNOVION PHARMACEUTICALS INC. | 2016-08-04 | — | — | US | disclosed |
| US-20160221947-A1 | TRIPLE REUPTAKE INHIBITORS AND METHODS OF THEIR USE | SUNOVION PHARMACEUTICALS INC. | 2016-08-04 | — | — | US | disclosed |
| US-20140107175-A1 | TRIPLE REUPTAKE INHIBITORS AND METHODS OF THEIR USE | SUNOVION PHARMACEUTICALS INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-8592608-B2 | Triple reuptake inhibitors and methods of their use | SUNOVION PHARMACEUTICALS INC. (US) | 2013-11-26 | — | — | US | disclosed |
| EP-2370405-B1 | TRIPLE REUPTAKE INHIBITORS AND METHODS OF THEIR USE | SUNOVION PHARMACEUTICALS INC (US) | 2013-05-01 | — | — | EP | disclosed |
| EP-2370405-B1 | TRIPLE REUPTAKE INHIBITORS AND METHODS OF THEIR USE | SUNOVION PHARMACEUTICALS INC (US) | 2013-05-01 | — | — | EP | disclosed |
| US-20110313013-A1 | TRIPLE REUPTAKE INHIBITORS AND METHODS OF THEIR USE | SUNOVION PHARMACEUTICALS INC. | 2011-12-22 | — | — | US | disclosed |
| US-20110313013-A1 | TRIPLE REUPTAKE INHIBITORS AND METHODS OF THEIR USE | SUNOVION PHARMACEUTICALS INC. | 2011-12-22 | — | — | US | disclosed |
| US-20110313013-A1 | TRIPLE REUPTAKE INHIBITORS AND METHODS OF THEIR USE | SUNOVION PHARMACEUTICALS INC. | 2011-12-22 | — | — | US | disclosed |
| EP-2370405-A1 | TRIPLE REUPTAKE INHIBITORS AND METHODS OF THEIR USE | Sunovion Pharmaceuticals Inc. (US) | 2011-10-05 | — | — | EP | disclosed |
| WO-2010075064-A1 | TRIPLE REUPTAKE INHIBITORS AND METHODS OF THEIR USE | SEPRACOR INC. (US) | 2010-07-01 | — | — | WO | disclosed |
| WO-2010075064-A1 | TRIPLE REUPTAKE INHIBITORS AND METHODS OF THEIR USE | SEPRACOR INC. (US) | 2010-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10428021-B2 | Triple reuptake inhibitors and methods of their use | SLC18A2, SLC6A2, SLC18A3 | SLC6A4 4/4885SLC6A3 5/4885SLC6A2 2/4885 |
| US-20180148407-A1 | TRIPLE REUPTAKE INHIBITORS AND METHODS OF THEIR USE | SLC18A2, SLC6A2, SLC18A3 | SLC6A4 4/4885SLC6A3 5/4885SLC6A2 2/4885 |
| US-20140107175-A1 | TRIPLE REUPTAKE INHIBITORS AND METHODS OF THEIR USE | SLC18A2, SLC6A2, SLC18A3 | SLC6A4 5/4885SLC6A3 4/4885SLC6A2 2/4885 |
| US-20160221947-A1 | TRIPLE REUPTAKE INHIBITORS AND METHODS OF THEIR USE | SLC18A2, SLC6A2, SLC18A3 | SLC6A4 4/4885SLC6A3 5/4885SLC6A2 2/4885 |
| US-20110313013-A1 | TRIPLE REUPTAKE INHIBITORS AND METHODS OF THEIR USE | SLC18A2, SLC6A2, SLC18A3 | SLC6A4 4/4885SLC6A3 5/4885SLC6A2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.